2,815 Amgen Inc. $AMGN Shares Sold by MRA Advisory Group

MRA Advisory Group lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 66.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,441 shares of the medical research company’s stock after selling 2,815 shares during the quarter. MRA Advisory Group’s holdings in Amgen were worth $608,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AMGN. Rational Advisors Inc. raised its holdings in Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after buying an additional 24 shares during the period. Beacon Financial Advisory LLC boosted its stake in Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after buying an additional 25 shares during the period. Legacy Financial Advisors Inc. increased its position in shares of Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after acquiring an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. increased its position in shares of Amgen by 1.4% during the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock valued at $705,000 after acquiring an additional 27 shares during the last quarter. Finally, Round Rock Advisors LLC increased its holdings in Amgen by 2.9% in the 2nd quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 28 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of research analyst reports. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. Guggenheim boosted their price objective on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a report on Monday, August 10th. Citigroup increased their target price on Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Barclays lifted their target price on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Finally, Morgan Stanley reduced their price target on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $385.79.

Amgen Stock Up 2.7%

AMGN stock traded up $10.81 during mid-day trading on Wednesday, reaching $413.42. The company had a trading volume of 992,761 shares, compared to its average volume of 2,752,233. The firm has a fifty day simple moving average of $411.44 and a 200 day simple moving average of $371.01. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company has a market capitalization of $223.51 billion, a price-to-earnings ratio of 25.66, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its AMG 513 obesity-drug study completed Phase 1. The milestone provides an additional potential growth opportunity in the competitive weight-loss market, although clinical efficacy and safety data remain important next steps. Amgen AMG 513 obesity trial article
• Positive Sentiment: Scotiabank raised its price target for Amgen from $450 to $500, signaling greater confidence in the company’s upside potential and supporting sentiment around the stock. Scotiabank raises Amgen price target
• Neutral Sentiment: Truist raised its target from $362 to $380 but maintained a Hold rating. The revised target remains below the recent trading level, limiting the bullish impact of the increase.
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating, while another report cited a $400 target. These views suggest analysts see limited near-term upside after Amgen’s strong run. Cantor Fitzgerald Amgen rating
• Neutral Sentiment: Amgen has become a heavily watched or “trending” stock on Zacks, which may increase trading attention but does not represent a fundamental change in the company’s outlook. Zacks Amgen trending stock article
• Negative Sentiment: Morgan Stanley lowered its target from $362 to $359 and retained an Equal Weight rating. The target implies substantial downside from current levels, reinforcing concerns that expectations and valuation may be elevated. Morgan Stanley Amgen price target report

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.